According to Monath, the new vaccine is likely to______. [originaltext] A new

A new vaccine for yellow fever is showing good results in tests. The new vaccine overcomes one of the biggest problems with the current version.
    Yellow fever is a deadly disease that occurs in much of South America and sub-Saharan Africa. A vaccine developed in the 1930s provides excellent protection, both for those living in affected areas and those traveling there. It’s made using a live but weakened form of the yellow fever virus.
    And that can lead to very serious side effects, says Thomas Monath of the US biotech firm, Xcellerex.
    Monath is the lead author of a research paper describing the latest clinical trials of a new yellow-fever shot, developed to avoid even those very rare fatal complications. Instead of the live virus used in the current vaccine, the virus in the new vaccine is killed. So the researchers found that the new vaccine is safer—it produced limited, relatively mild side effects—while it stimulated the body’ s immune response. If final regulatory approval is granted, the new vaccine could be used both in countries where yellow fever is endemic, as well as for travelers visiting those areas. Pharmaceutical pricing is always hard to predict, but Monath says the new vaccine is likely to cost somewhat more than the current vaccine because it will be more expensive to make and because it’s a better vaccine.